MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10637-018-0586-9

Медицинская библиотека · Investigational new drugs · 2018

Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.

Tanaka Midori, Ishii Hidenobu, Moribuchi Hayato, Naito Yoshiko, Matsuo Norikazu, Nakamura Masayuki, Tokito Takaaki, Azuma Koichi, Yamada Kazuhiko, Hoshino Tomoaki

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

Small-cell lung cancer (SCLC) combined with epidermal growth factor receptor (EGFR) mutations is extremely rare, and standard chemotherapeutic strategies have not yet been established. In the present study, we report a case of a 67-year-old man who presented with combined SCLC with EGFR mutation (exon 19 deletion). Systemic chemotherapy with cisplatin and irinotecan was initiated as first-line chemotherapy, and computed tomography findings revealed tumor shrinkage after two cycles of chemotherapy. However, after the third cycle of the treatment, disease progression was observed including the appearance of pleural and pericardial effusion. Cytologic examination of pleural and pericardial effusion revealed adenocarcinoma and no characteristics of SCLC, and an EGFR mutation was detected, in line with the initial diagnosis. Afatinib was then administered as second-line chemotherapy, which resulted in a partial response that lasted for 6 months. Re-biopsy after resistance to first-line chemotherapy suggested that the adenocarcinoma component harboring the EGFR mutation became dominant in association with disease progression, and afatinib provided clinical efficacy as second-line chemotherapy.

Для цитирования: Tanaka Midori, Ishii Hidenobu, Moribuchi Hayato, Naito Yoshiko, Matsuo Norikazu, Nakamura Masayuki, Tokito Takaaki, Azuma Koichi, Yamada Kazuhiko, Hoshino Tomoaki. Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.. Investigational new drugs. 2018. DOI: 10.1007/s10637-018-0586-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.